Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

When A Recall Hits, Embrace Your Regulator For The Common Good: Patient Safety

Executive Summary

When a device-maker initiates a medical device recall, it's wise for the firm to work hand-in-hand with regulators to ensure that the product is removed from the market before it causes troubles for users. Chris Harvey of Stericycle ExpertSOLUTIONS offers tips in this Medtech Insight guest column for making sure that happens. He highlights five cardinal rules to ensure a smooth recall process.

You may also be interested in...



Device-Makers Can Be 'Recall Ready' With This Step-By-Step Guidance From FDA

From general preparations to the development of correction and removal initiation procedures, the US agency is offering recommendations to firms on how to recall a problem product. In its new draft guidance, the FDA says it's "critical" for manufacturers to be "recall ready."

Q4 Recalls Snapshot: Recalled Devices At 6-Year Low; Software Issues Remain Top Recall Reason

There were 152 recalls in the fourth quarter of 2017, a 9% decline from Q3, when 167 corrections & removals were initiated by device-makers. The Q4 figure also represents the lowest number of recall events in a quarter since Q4 2011. Check out our Q4 recalls infographic.

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel